Translational Research On Hereditary Cancer |

Publications

2025

Esteban-Villarrubia, J, Castro, E (2025).

Efficacy at a cost?-quality of life implications of PARP inhibition in the homologus recombination repair (HRR) cohort of TALAPRO-2

Translational Andrology and Urology. Editorial Material. 14(11):3453-3456.
[doi:10.21037/tau-2025-645]

Yazgan, SC, Yekedüz, E, Akkus, E, Sun, M, Gillessen, S, Fizazi, K, Mckay, RR, Ay, C, Castro, E, Agarwal, N, Choueiri, TK, Ürün, Y (2025).

Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis

Esmo Open. Review. 10(10).
[doi:10.1016/j.esmoop.2025.105811]

Olmos, D, Lorente, D, Jambrina, A, Tello-Velasco, D, Ovejero-Sánchez, M, Gonzalez-Ginel, I, Romero-Laorden, N, Nunes-Carneiro, D, Balongo, M, Gutierrez-Pecharromán, AM, Llácer, C, Prieto, JD, Perez-Argüelles, D, Arco, FAD, Miguel-Masiá, J, Ruiz-Vico, M, Santos, R, Esteban-Villarrubia, J, Gonzalez-Billalabeitia, E, Jürgens, A, Capone, C, Trevisan, M, Van Sanden, S, Stulnig, G, Hernández, D, López-Casas, PP, Rodriguez-Antolin, A, Castellano, DE, Herrera-Imbroda, B, Castro, E (2025).

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes

ANNALS OF ONCOLOGY. Article. 36(10).
[doi:10.1016/j.annonc.2025.05.534]

Lopez-Valcarcel, M, Lopez-Campos, F, Zafra-Martín, J, Belmonte, IC, Subiela, JD, Ruiz-Vico, M, Alonso, SF, Cuesta, JAG, Couñago, F (2025).

Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment

International Journal Of Molecular Sciences. Review. 26(16).
[doi:10.3390/ijms26167667]

Pinto, A, Domínguez, M, Gómez-Iturriaga, A, Rodriguez-Vida, A, Vallejo-Casas, JA, Castro, E (2025).

The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. Review. 210.
[doi:10.1016/j.critrevonc.2025.104678]

Castro, E, Lorente, D, Olmos, D (2025).

PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the Chaff

EUROPEAN UROLOGY. Editorial Material. 87(6):641-642.
[doi:10.1016/j.eururo.2025.01.012]

Zacchi, F, Abida, W, Antonarakis, ES, Bryce, AH, Castro, E, Cheng, HH, Shandhu, S, Mateo, J (2025).

Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer

European Urology Oncology. Article. 8(3):818-828.
[doi:10.1016/j.euo.2024.11.011]

Castro, E, Orji, C, Ribbands, A, Butcher, J, Walley, M, Li, WY, Ghate, SR (2025).

Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe

FUTURE ONCOLOGY. Article. 21(9):1085-1099.
[doi:10.1080/14796694.2025.2470616]

Castro, E, Wang, D, Walsh, S, Craigie, S, Haltner, A, Nazari, J, Niyazov, A, Samjoo, IA (2025).

Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC

FUTURE ONCOLOGY. Article. 21(9):1075-1084.
[doi:10.1080/14796694.2025.2471200]

Bolek, H, Yazgan, SC, Ceylan, F, Esteban-Villarrubia, J, Arslan, C, Kus, T, Tural, D, Sendur, MAN, Kucuk, NO, Özdemir, EÇ, Castro, E, Yekeduz, E, Ürün, Y (2025).

Comparison of two alternative sequences with cabazitaxel and 177Lu-P-SMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS)

EUROPEAN JOURNAL OF CANCER. Article. 217.
[doi:10.1016/j.ejca.2025.115226]

Ruiz-Vico, M, Wetterskog, D, Orlando, F, Thakali, S, Wingate, A, Jayaram, A, Cremaschi, P, Vainauskas, O, Brighi, N, Castellano-Gauna, D, Åström, L, Matveev, VB, Bracarda, S, Esen, A, Feyerabend, S, Senkus, E, Piqueras, MLB, Gupta, S, Wenstrup, R, Boysen, G, Martins, K, Iwata, K, Chowdhury, S, Gourgioti, G, Serikoff, A, Gonzalez-Billalabeitia, E, Merseburger, AS, Demichelis, F, Attard, G (2025).

Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial

European Urology Oncology. Article. 8(1):135-144.
[doi:10.1016/j.euo.2024.08.006]

Francini, E, Agarwal, N, Castro, E, Cheng, HH, Chi, KN, Clarke, N, Mateo, J, Rathkopf, D, Saad, F, Tombal, B (2025).

Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review

EUROPEAN UROLOGY. Review. 87(1):29-46.
[doi:10.1016/j.eururo.2024.09.008]

2024

Castro, E, Wang, D, Walsh, S, Craigie, S, Haltner, A, Nazari, J, Niyazov, A, Samjoo, IA (2024).

Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison

PROSTATE CANCER AND PROSTATIC DISEASES. Article.
[doi:10.1038/s41391-024-00924-x]

Esteban-Villarrubia, J, Ballesteros, PA, Martín-Serrano, M, Vico, MR, Funes, JM, de Velasco, G, Castro, E, Olmos, D, Castellano, D, González-Billalabeitia, E (2024).

Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer

Immuno. Review. 4(4):444-460.
[doi:10.3390/immuno4040028]

Castro, E, Figliuzzi, R, Walsh, S, Craigie, S, Nazari, J, Niyazov, A, Samjoo, IA (2024).

Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer

ONCOLOGIST. Review. 30.
[doi:10.1093/oncolo/oyae321]

Manso, LS, Alfranca, A, Moreno-Pérez, I, Ruiz-Vico, M, Velasco, C, Toquero, P, Pacheco, M, Zapatero, A, Aldave, D, Celada, G, Albers, E, de la Maza, MDF, García, J, Castro, E, Olmos, D, Colomer, R, Romero-Laorden, N (2024).

Immunome profiling in prostate cancer: a guide for clinicians

Frontiers in immunology. Review. 15:1398109-1398109.
[doi:10.3389/fimmu.2024.1398109]

van de Haar, J, Roepman, P, Andre, F, Balmaña, J, Castro, E, Chakravarty, D, Curigliano, G, Czarnecka, AM, Dienstmann, R, Horak, P, Marchiò, C, Italiano, A, Monkhorst, K, Pritchard, CC, Reardon, B, Russnes, HEG, Sirohi, B, Sosinsky, A, Spanic, T, Turnbull, C, Van Allen, E, Westphalen, CB, Tamborero, D, Mateo, J (2024).

ESMO Recommendations on clinical reporting of genomic test results for solid cancers

ANNALS OF ONCOLOGY. Article. 35(11):954-967.
[doi:10.1016/j.annonc.2024.06.018]

Castro, E, Ellis, J, Craigie, S, Haltner, A, Nazari, J, Niyazov, A, Samjoo, IA (2024).

Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer

ONCOLOGIST. Review. 30(3).
[doi:10.1093/oncolo/oyae237]

Montero-Hidalgo, AJ, Jiménez-Vacas, JM, Gómez-Gómez, E, Porcel-Pastrana, F, Sáez-Martinez, P, Pérez-Gómez, JM, Fuentes-Fayos, AC, Blázquez-Encinas, R, Sánchez-Sánchez, R, González-Serrano, T, Castro, E, López-Soto, PJ, Carrasco-Valiente, J, Sarmento-Cabral, A, Martinez-Fuentes, AJ, Eyras, E, Castaño, JP, Sharp, A, Olmos, D, Gahete, MD, Luque, RM (2024).

SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer

Science Advances. Article. 10(40).
[doi:10.1126/sciadv.ado8231]

Samjoo, IA, Disher, T, Castro, E, Ellis, J, Paganelli, S, Nazari, J, Niyazov, A (2024).

Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer

CLINICAL GENITOURINARY CANCER. Review. 22(5):102137-102137.
[doi:10.1016/j.clgc.2024.102137]

Castro, E (2024).

PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers

European Urology Focus. Editorial Material. 10(4):504-505.
[doi:10.1016/j.euf.2024.08.005]

Bancroft EK, Page EC, Brook MN, Pope J, Thomas S, Myhill K, Helfand BT, Talaty P, Ong KR, Douglas E, Cook J, Rosario DJ, Salinas M, Buys SS, Anson J, Davidson R, Longmuir M, Side L, Eccles DM, Tischkowitz M, Taylor A, Cruellas M, Ballestero EP, Cleaver R, Varughese M, Barwell J, LeButt M, Greenhalgh L, Hart R, Azzabi A, Jobson I, Cogley L, Evans DG, Rothwell J, Taylor N, Hogben M, Saya S, Eeles RA, Aaronson NK (2024).

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.

BJU INTERNATIONAL. Article. 134(3):484-500.
[doi:10.1111/bju.16432]

Cheng, HH, Shevach, JW, Castro, E, Couch, FJ, Domchek, SM, Eeles, RA, Giri, VN, Hall, MJ, King, MC, Lin, DW, Loeb, S, Morgan, TM, Offit, K, Pritchard, CC, Schaeffer, EM, Szymaniak, BM, Vassy, JL, Katona, BW, Maxwell, KN (2024).

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review

JAMA oncology. Review. 10(9):1272-1281.
[doi:10.1001/jamaoncol.2024.2185]

Mosele, MF, Westphalen, CB, Stenzinger, A, Barlesi, F, Bayle, A, Bieche, I, Bonastre, J, Castro, E, Dienstmann, R, Krämer, A, Czarnecka, AM, Meric-Bernstam, F, Michiels, S, Miller, R, Normanno, N, Reis, J, Remon, J, Robson, M, Rouleau, E, Scarpa, A, Serrano, C, Mateo, J, Andre, F (2024).

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

ANNALS OF ONCOLOGY. Article. 35(7):588-606.
[doi:10.1016/j.annonc.2024.04.005]

Romero-Laorden, N, Lorente, D, de Velasco, G, Lozano, R, Herrera, B, Puente, J, López, PP, Medina, A, Almagro, E, Gonzalez-Billalabeitia, E, Villla-Guzman, JC, González-del-Alba, A, Borrega, P, Laínez, N, Fernández-Freire, A, Hernández, A, Rodriguez-Vida, A, Chirivella, I, Fernandez-Parra, E, López-Campos, F, Pacheco, MI, Morales-Barrera, R, Fernández, O, Villatoro, R, Luque, R, Hernando, S, Castellano, DC, Castro, E, Olmos, D (2024).

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

European Urology Oncology. Article. 7(3):447-455.
[doi:10.1016/j.euo.2023.09.015]

Iglesias-Corral, D, García-Valles, P, Arroyo-Garrapucho, N, Bueno-Martínez, E, Ruiz-Robles, JM, Ovejero-Sánchez, M, González-Sarmiento, R, Herrero, AB (2024).

Chloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death

Frontiers in oncology. Article. 14:1390518-1390518.
[doi:10.3389/fonc.2024.1390518]

Olmos, D, Lorente, D, Alameda, D, Cattrini, C, Romero-Laorden, N, Lozano, R, Lopez-Casas, PP, Jambrina, A, Capone, C, Vanden Broecke, AM, Trevisan, M, Van Sanden, S, Juergens, A, Herrera-Imbroda, B, Castro, E (2024).

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes

ANNALS OF ONCOLOGY. Article. 35(5):458-472.
[doi:10.1016/j.annonc.2024.01.011]

Casadei, C, Scarpi, E, Conteduca, V, Gurioli, G, Cursano, MC, Brighi, N, Lolli, C, Schepisi, G, Basso, U, Fornarini, G, Bleve, S, Farolfi, A, Altavilla, A, Burgio, SL, Giunta, EF, Gianni, C, Filograna, A, Ulivi, P, Olmos, D, Castro, E, De Giorgi, U (2024).

Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study

European Urology Open Science. Article. 61:44-51.
[doi:10.1016/j.euros.2024.01.015]

Bourlon, MT, Valdez, P, Castro, E (2024).

Development of PARP inhibitors in advanced prostate cancer

Therapeutic Advances in Medical Oncology. Review. 16.
[doi:10.1177/17588359231221337]

de la Maza, MDF, Gracia, JLP, Miñana, B, Castro, E (2024).

PARP inhibitors alone or in combination for prostate cancer

Therapeutic Advances in Urology. Review. 16.
[doi:10.1177/17562872241272929]

Calabrese, M, Saporita, I, Turco, F, Gillessen, S, Castro, E, Vogl, UM, Di Stefano, RF, Carfi, FM, Poletto, S, Farinea, G, Tucci, M, Buttigliero, C (2024).

Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer

International Journal Of Molecular Sciences. Review. 25(1).
[doi:10.3390/ijms25010078]

2023

Chávarri-Guerra, Y, Bourlon, MT, Rodríguez-Olivares, JL, Orozco, L, Bazua, D, Rodríguez-Faure, A, Alcalde-Castro, MJ, Castro, E, Castillo, D, Herzog, J, Weitzel, J (2023).

Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer

CLINICAL GENITOURINARY CANCER. Article. 21(5):569-573.
[doi:10.1016/j.clgc.2023.05.012]

Beije, N, Abida, W, Antonarakis, ES, Castro, E, de Wit, R, Fizazi, K, Gillessen, S, Hussain, M, Mateo, J, Morris, MJ, Olmos, D, Sartor, O, Sharp, A, Sweeney, CJ, de Bono, JS (2023).

PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.

EUROPEAN UROLOGY. Editorial Material. 84(3):253-256.
[doi:10.1016/j.eururo.2023.03.038]

Chi, KN, Sandhu, S, Smith, MR, Attard, G, Saad, M, Olmos, D, Castro, E, Roubaud, G, Gomes, AJPD, Small, EJ, Rathkopf, DE, Gurney, H, Jung, W, Mason, GE, Dibaj, S, Wu, D, Diorio, B, Urtishak, K, del Corral, A, Francis, P, Kim, W, Efstathiou, E (2023).

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

ANNALS OF ONCOLOGY. Article. 34(9):772-782.
[doi:10.1016/j.annonc.2023.06.009]

Smith, MR, Sandhu, S, George, DJ, Chi, KN, Saad, F, Thiery-Vuillemin, A, Stáhl, O, Olmos, D, Danila, DC, Gafanov, R, Castro, E, Moon, H, Joshua, AM, Mason, GE, Espina, BM, Liu, Y, Lopez-Gitlitz, A, Francis, P, Bevans, KB, Fizazi, K (2023).

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects

Journal of Managed Care & Specialty Pharmacy. Article. 29(7):758-768.